Piperidinyl-Indole Derivatives for Factor B Inhibition in IgA Nephropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IgA nephropathy (IgAN) do not effectively target the underlying complement pathway activation, particularly the alternative pathway, which contributes to disease progression.
Innovation Solution
The use of piperidinyl-indole derivatives, specifically compounds of Formula (I) or their pharmaceutically acceptable salts, to inhibit factor B and suppress the amplification of the complement system, thereby treating or preventing IgAN.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for IgAN are used, then general symptom management is achieved, but the underlying complement pathway activation is not effectively targeted
Solution Approach 1:
The patent applies parameter changes by introducing a novel molecular compound (piperidinyl-indole derivative) with specific chemical structure parameters that enable selective inhibition of factor B. This compound represents a significant parameter change from conventional treatments, achieving reliable targeting of the complement alternative pathway through its specific molecular properties and mechanism of action.
2Reliability
If factor B inhibition is implemented, then complement system amplification is suppressed, but treatment specificity must be maintained
Solution Approach 1:
The patent applies local quality by designing a compound with specific functional groups and molecular characteristics that confer selective affinity for factor B. The piperidinyl-indole structure contains specific local chemical properties (hydrophobic regions, hydrogen bonding capabilities, steric features) that enable selective binding to factor B while sparing other complement components, thus achieving reliable suppression of complement amplification with minimized harmful effects.
Solution Approach 2:
The piperidinyl-indole derivative acts as an intermediary molecule that mediates the inhibition between the therapeutic agent and factor B. This intermediary compound provides a controlled and specific interaction with factor B, allowing suppression of complement system amplification while maintaining treatment safety through its intermediate binding affinity and selective mechanism.
Data Source
AI summary
The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).